Rabbit Anti-Human Tenascin-R (a.a. 1270-1350) Polyclonal antibody

Name: Rabbit Anti-Human Tenascin-R (a.a. 1270-1350) Polyclonal antibody
SKU: DPABH-20243
Rating: 5 (1 reviews)

Rabbit Anti-Human Tenascin-R (a.a. 1270-1350) Polyclonal antibody for IHC, IF, ELISA

COA

SDS

Datasheet

Key features and details

Host: Rabbit
Target: Human Tenascin-R
Application: IHC, IF, ELISA

Summary

Specifications

Antibody Isotype

IgG

Species Reactivity

Human; Mouse; Rat

Immunogen

Synthetic peptide from human protein at AA range: 1270-1350

Conjugate

Unconjugated

Applications

Application Notes

IHC-P: 1:50-200
ELISA: 1:10000-20000
IF: 1:50-200

Target

Alternative Names

TNR; tenascin R (restrictin, janusin); tenascin-R; janusin; restrictin; TN-R; MGC149328

Citations

Have you cited DPABH-20243 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A photoelectrochemical methanol fuel cell based on aligned TiO2 nanorods decorated graphene photoanode

CHEMICAL COMMUNICATIONS

Authors: Li, Xinyuan; Wang, Guowen; Jing, Lin; Ni, Wei; Yan, Huan; Chen, Chao; Yan, Yi-Ming

Abstract

We report the photoelectrochemical (PEC) oxidation of methanol on a rationally designed graphene-TiO2 nanorod array (G-TNR) photoanode. A PEC methanol fuel cell was constructed by coupling the G-TNR photoanode with a cathode. This study raises a conceptual fuel cell that realizes the synergistic energy conversion of chemical energy and solar energy.

Dynamic changes in F-18-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection

RADIATION ONCOLOGY

Authors: Morita, Takahiro; Kurihara, Hiroaki; Hiroi, Kenta; Honda, Natsuki; Igaki, Hiroshi; Hatazawa, Jun; Arai, Yasuaki; Itami, Jun

Abstract

Background: We evaluated dynamic changes in F-18-borono-L-phenylalanine (F-18-BPA) uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck (SCC) and malignant melanoma (MM) during boron neutron capture therapy (BNCT) patient selection. Methods: Dynamic changes in the maximum standardized uptake value (SUVmax), tumor-to-normal tissue ratio (TNR), and tumor-to-blood pool ratio (TBR) for F-18-BPA were evaluated in 20 patients with SCC and 8 patients with MM. Results: SUVmax in SCC tumors decreased significantly from 30 to 120 min. There was a non-statistically significant decrease in SUVmax for SCC tumors from 30 to 60 min and from 60 to 120 min. Patients with MM had nonsignificant SUVmax changes in F-18-BPA uptake on delayed imaging. Nonsignificant F-18-BPA TNR and TBR changes were seen in patients with SCC and MM. Conclusions: Dynamic changes in SUVmax for F-18-BPA uptake had a washout pattern in SCC and a persistent pattern in MM. Dynamic F-18-BPA -PET studies should be performed to investigate the pharmacokinetics of F-18-BPA in humans and select appropriate candidates who may benefit from BNCT.